# Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-up

> **NCT07678268** · PHASE4 · RECRUITING · sponsor: **Instituto Mexicano del Seguro Social** · enrollment: 78 (estimated)

## Conditions studied

- HIV Infection
- Antiretroviral Therapy
- Lentivirus Infections

## Interventions

- **DRUG:** Dual therapy: darunavir/cobicistat + lamivudine
- **DRUG:** Triple therapy: darunavir/cobicistat plus tenofovir alafenamide/emtricitabine

## Key facts

- **NCT ID:** NCT07678268
- **Lead sponsor:** Instituto Mexicano del Seguro Social
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-10
- **Primary completion:** 2026-07-10
- **Final completion:** 2026-12-10
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2026-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07678268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07678268, "Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-up". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07678268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*